Literature DB >> 25624711

Role of E3 ubiquitin ligases in gastric cancer.

Ya-Chao Hou1, Jing-Yu Deng1.   

Abstract

E3 ubiquitin ligases have an important role in carcinogenesis and include a large family of proteins that catalyze the ubiquitination of many protein substrates for targeted degradation by the 26S proteasome. So far, E3 ubiquitin ligases have been reported to have a role in a variety of biological processes including cell cycle regulation, cell proliferation, and apoptosis. Recently, several kinds of E3 ubiquitin ligases were demonstrated to be generally highly expressed in gastric cancer (GC) tissues and to contribute to carcinogenesis. In this review, we summarize the current knowledge and information about the clinical significance of E3 ubiquitin ligases in GC. Bortezomib, a proteasome inhibitor, encouraged the evaluation of other components of the ubiquitin proteasome system for pharmaceutical intervention. The clinical value of novel treatment strategies targeting aberrant E3 ubiquitin ligases for GC are discussed in the review.

Entities:  

Keywords:  E3 ubiquitin ligases; Gastric cancer; Oncogene; Target therapy; Tumor suppressor gene

Mesh:

Substances:

Year:  2015        PMID: 25624711      PMCID: PMC4299330          DOI: 10.3748/wjg.v21.i3.786

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  99 in total

Review 1.  SCF and Cullin/Ring H2-based ubiquitin ligases.

Authors:  R J Deshaies
Journal:  Annu Rev Cell Dev Biol       Date:  1999       Impact factor: 13.827

2.  Ubiquitin ligase MKRN1 modulates telomere length homeostasis through a proteolysis of hTERT.

Authors:  Jun Hyun Kim; Sun-Mi Park; Mi Ran Kang; Sue-Young Oh; Tae H Lee; Mark T Muller; In Kwon Chung
Journal:  Genes Dev       Date:  2005-04-01       Impact factor: 11.361

3.  COP1 functions as a FoxO1 ubiquitin E3 ligase to regulate FoxO1-mediated gene expression.

Authors:  Satomi Kato; Jixin Ding; Evan Pisck; Ulupi S Jhala; Keyong Du
Journal:  J Biol Chem       Date:  2008-09-24       Impact factor: 5.157

4.  Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B).

Authors:  Aminah Jatoi; Shaker R Dakhil; Nathan R Foster; Cynthia Ma; Kendrith M Rowland; Dennis F Moore; Anthony J Jaslowski; Sachdev P Thomas; Mark D Hauge; Patrick J Flynn; Philip J Stella; Steven R Alberts
Journal:  J Thorac Oncol       Date:  2008-05       Impact factor: 15.609

5.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.

Authors:  Teresa A Soucy; Peter G Smith; Michael A Milhollen; Allison J Berger; James M Gavin; Sharmila Adhikari; James E Brownell; Kristine E Burke; David P Cardin; Stephen Critchley; Courtney A Cullis; Amanda Doucette; James J Garnsey; Jeffrey L Gaulin; Rachel E Gershman; Anna R Lublinsky; Alice McDonald; Hirotake Mizutani; Usha Narayanan; Edward J Olhava; Stephane Peluso; Mansoureh Rezaei; Michael D Sintchak; Tina Talreja; Michael P Thomas; Tary Traore; Stepan Vyskocil; Gabriel S Weatherhead; Jie Yu; Julie Zhang; Lawrence R Dick; Christopher F Claiborne; Mark Rolfe; Joseph B Bolen; Steven P Langston
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

Review 6.  MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy.

Authors:  Steffan T Nawrocki; Patrick Griffin; Kevin R Kelly; Jennifer S Carew
Journal:  Expert Opin Investig Drugs       Date:  2012-07-16       Impact factor: 6.206

7.  Characterization of human constitutive photomorphogenesis protein 1, a RING finger ubiquitin ligase that interacts with Jun transcription factors and modulates their transcriptional activity.

Authors:  Elisabetta Bianchi; Simona Denti; Raffaella Catena; Grazisa Rossetti; Simona Polo; Sona Gasparian; Stella Putignano; Lars Rogge; Ruggero Pardi
Journal:  J Biol Chem       Date:  2003-03-03       Impact factor: 5.157

8.  The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme.

Authors:  Dong Yang; Mingjia Tan; Gongxian Wang; Yi Sun
Journal:  PLoS One       Date:  2012-03-22       Impact factor: 3.240

9.  The checkpoint protein Chfr is a ligase that ubiquitinates Plk1 and inhibits Cdc2 at the G2 to M transition.

Authors:  Dongmin Kang; James Chen; Jim Wong; Guowei Fang
Journal:  J Cell Biol       Date:  2002-01-21       Impact factor: 10.539

10.  Targeting the neddylation pathway to suppress the growth of prostate cancer cells: therapeutic implication for the men's cancer.

Authors:  Xiaofang Wang; Lihui Li; Yupei Liang; Chunjie Li; Hu Zhao; Dingwei Ye; Menghong Sun; Lak Shin Jeong; Yan Feng; Shen Fu; Lijun Jia; Xiaomao Guo
Journal:  Biomed Res Int       Date:  2014-06-29       Impact factor: 3.411

View more
  3 in total

Review 1.  Ubiquitin proteasome system research in gastrointestinal cancer.

Authors:  Jia-Ling Zhong; Chang-Zhi Huang
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

2.  Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.

Authors:  Li Yang; Jing Chen; Xiaoyan Han; Enfan Zhang; Xi Huang; Xing Guo; Qingxiao Chen; Wenjun Wu; Gaofeng Zheng; Donghua He; Yi Zhao; Yang Yang; Jingsong He; Zhen Cai
Journal:  Protein Cell       Date:  2018-02-13       Impact factor: 14.870

Review 3.  The many substrates and functions of NEDD4-1.

Authors:  Xi Huang; Jing Chen; Wen Cao; Li Yang; Qingxiao Chen; Jingsong He; Qing Yi; He Huang; Enfan Zhang; Zhen Cai
Journal:  Cell Death Dis       Date:  2019-12-02       Impact factor: 8.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.